⌕
Recursion Pharmaceuticals · RXRX · Nasdaq
Tenet 53 · Mixed
Compare
$2.91−8.79%At closeTenet 53 · Mixed
$2.91−0.28 (−8.79%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Recursion Pharmaceuticals (RXRX) Stock

Recursion Pharmaceuticals (RXRX) closed at $2.91 on Nov 16, 2026; its Tenet Score is 53 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

21 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$2.91
Nov 16, 2026
Market cap
$2.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
2.77 – 5.24
low → high · as of close, Nov 13, 2026
Tenet Score
53/100
Mixed · 313 Healthcare peers

Industry: Drugs

Recursion Pharmaceuticals Inc scores 53/100. Mixed. Strongest on value and financial health, quality is the soft spot versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
53/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
78
Quality
14
Health
72
Growth
48

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityFHealthBGrowthDMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.2×
price to book value
P/S
29.1×
price to fiscal 2025 sales
ROE
−49%
return on equity
Operating margin
−867.9%
fiscal 2025, before interest and tax
Net margin
−697.1%
of revenue kept
Current ratio
5.01
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 76 US ETFs · top wrappers by weightSee all ETFs holding RXRX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Recursion Pharmaceuticals in?

Recursion Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Recursion Pharmaceuticals' Tenet Score?

Recursion Pharmaceuticals' Tenet Score is 53 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.